---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-22-000061"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2022-09-07T23:59:59+00:00"
generated_at: "2026-06-23T14:26:16.996594+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcutis acquires Ducentis for ~$30M upfront; DS-234 for atopic dermatitis

## Summary
- Upfront consideration ~$30M (~$16M cash + ~$14M in stock); contingent milestones up to ~$400M.
- DS-234 is a CD200R agonist (checkpoint agonism) targeting atopic dermatitis, a large underserved market.
- Arcutis had ~$283M cash as of June 2022 plus $285M from Aug financings; deal not material to financial plans.
- Closing expected Q3 2022; no stockholder approval required; Ducentis CSO retained as consultant.

## SEC filing metadata
- accession: 0001787306-22-000061
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2022-09-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000061/0001787306-22-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000061/arqt-20220907.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-22-000061
- JSON: https://secwatch.observer/filing/0001787306-22-000061.json
- Plain text: https://secwatch.observer/filing/0001787306-22-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.